GlassScriptPhysician profile
Janja Viltuznik
NPI 1639182702
$12,662.79
in general payments reported to CMS, 2019-2025
41 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 90% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $2,033 · 2021: $1,957 · 2022: $1,511 · 2023: $1,571 · 2024: $2,255 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,366.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,616.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,387.72 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,351.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,201.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.01 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $631.94 | 2019-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $549.13 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $532.76 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $478.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $461.94 | 2019-2021 | |
| Novo Nordisk INC | $324.28 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $310.92 | 2019-2020 | |
| Amgen INC. | $200.32 | 2019-2024 | Repatha |
| Sumitomo Pharma America, INC. | $175.44 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $174.34 | 2023-2024 | Watchman Flx |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janja Viltuznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.